Universal influenza vaccine using cold-adapted live-attenuated virus
US10953086B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2019 |
| Grant date | Mar 23, 2021 |
| Priority date | — |
| Expiry date | Feb 1, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01018
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a universal influenza vaccine composition and corresponding methods comprising at least one attenuated live-attenuated influenza vaccine. The vaccine composition can exhibit a cross-protective effect against a wide range of influenza viruses and can ensure a strong protection efficacy, a wide range of protection, and safety. In addition, a vaccination method of heterologous live vaccines of the present invention induces various immunological effects so that cross-immunogenicity and cross-protective ability are remarkably increased, and thus is expected to be usefully utilized as a universal influenza prevention method. A person who has a basal immunity through infection with an influenza virus or vaccination with an influenza vaccine can be regarded as being in a state where primary vaccination has already been performed, single vaccination with a live vaccine induces an enhanced cross-immune response, and thus it is possible to expect a wide range of protective effects against various viruses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.